Moxonidine modulates cytokine signalling and effects on cardiac cell viability

Immunodetection and subcellular distribution of imidazoline receptor proteins with three antibodies in mouse and human brains: Effects of treatments with I1- and I2-imidazoline drugs

“…In general agreement with previous studies (Table 3; e.g. Aceros et al, 2014;Ivanov et al, 1998b), the contents of 167 kDa, 105/115 kDa, and 85 kDa I 1 -IRs in mouse brain cortex were found to be modulated by treatment with I 1 -IR selective drugs (moxonidine, efaroxan) but not with selective or preferentially I 2 -IR drugs (BU-224, LSL 61122, idazoxan; with some exception for idazoxan). This modulation of I 1 -IR proteins by I 1 -drugs (see correlation analyses in Figure 7(f)) is also in line with previous studies which reported similar findings relating these proteins with I 1 -radioligand binding sites (Table 3; e.g.…”

“…↓or↑: modest decrease or increase (<20 %); ↓↓or↑↑: marked decrease or increase (>30 %); ≈: no significant change. Abbreviations. corr: correlation between Bmax and IR protein; Mox: moxonidine; Efa: efaroxan; Ida: idazoxan Selected references: 1 (Ruiz et al, 1993), 2 (Escribá et al, 1994), 3 (García-Sevilla et al, 1995a,b), 4 (Escribá et al, 1995), 5 (Sastre et al, 1996), 6 (Escribá et al, 1996), 7 (García-Sevilla et al, 1996a,b), 8 (Ivanov et al, 1998a,b), 9 (Boronat et al, 1998), 10 (García-Sevilla et al, 1998), 11 (García-Sevilla et al, 1999), 12 (Piletz et al, 1999), 13 (Barturen et al, 1999), 14 (Halaris et al, 1999), 15 (Olmos et al, 1999a), 16 (Piletz et al, 2000a,b), 17 (Alahari et al, 2000), 18 (El-Ayoubi et al, 2002), 19 (Tyacke et al, 2002), 20 (Sano et al, 2002), 21 (García-Sevilla and Ferrer-Alcón, 2003), 22 (Piletz et al, 2003), 23 (Ma et al, 2003), 24 (El-Ayoubi et al, 2003), 25 (Dontenwill et al, 2003a,b), 26 (Chen et al, 2003), 27 (El-Ayoubi et al, 2004), 28 (Lim and Hong, 2004), 29 (Zhang and Abdel-Rahman, 2006), 30 (Sun et al, 2007), 31 (Zhang and Abdel-Rahman, 2008), 32 (Wang et al, 2009), 33 (Li and Zhang, 2011), 34 (Ding et al, 2013), 35 (Wang et al, 2013), 36 (Mar et al, 2013), 37 (Aceros et al, 2014), 38 (Chen et al, 2014). …”

“…17 (Alahari et al, 2000), 18 (El-Ayoubi et al, 2002), 19 (Tyacke et al, 2002), 20 (Sano et al, 2002), 21 (García-Sevilla and Ferrer-Alcón, 2003), 22 , 23 (Ma et al, 2003), 24 (El-Ayoubi et al, 2003), 25 (Dontenwill et al, 2003a,b), 26 (Chen et al, 2003), 27 (El-Ayoubi et al, 2004, 28 (Lim and Hong, 2004), 29 (Zhang and Abdel-Rahman, 2006), 30 (Sun et al, 2007), 31 (Zhang and Abdel-Rahman, 2008), 32 (Wang et al, 2009), 33 (Li and Zhang, 2011), 34 (Ding et al, 2013), 35 (Wang et al, 2013), 36 (Mar et al, 2013), 37 (Aceros et al, 2014), 38 (Chen et al, 2014).…”

Imidazoline Receptor System: The Past, the Present, and the Future

“…McLean et al (2014) confirmed that another selective I 1 receptor agonist, S43126 (2-[40-methoxyphenyl]-4,5-dihydro-1H-imidazole), has an antiproliferative effect on PC12 cells. Using cardiomyocytes from rat neonates, the selective I 1 receptor agonist moxonidine protects against cell death induced by starvation or by interleukin-1b (Aceros et al, 2014). In summary, it appears that the activation of I 1 receptors most often has a protective effect on cell viability.…”

Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment

“…Although these drugs have totally different molecular targets, as these results predicted, the potential of these drugs in immune modulation has been supported by an increasing number of recently published articles. For example, histone deacetylase inhibitors (HDACs) are regarded as promising drug candidates by combining them with immunotherapy 30 – 33 , and moxonidine 34 – 37 , β-escin 38 , 39 and AH23848 40 – 46 have shown potential in cytokine signaling modulation and inflammation regulation in published reports. However, whether these drugs can directly affect antitumor immunity in vivo and whether they can enhance the effect of immunotherapy still need to be further explored.…”